Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05624125 · ClinicalTrials.gov registry record · NA

BEETroot Juice to Reverse Functional Impairment in PAD

A NA study of Peripheral Artery Disease, sponsored by Northwestern University.

Recruiting
Registry status
NA
Development phase
210
Enrollment target
4
Study locations

NCT05624125 is a NA study of Peripheral Artery Disease that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 210 participants, above the 123-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (71% higher). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05624125, a NA study of Peripheral Artery Disease, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
NA
Development phase
210 participants
Enrollment target
4
Study locations

Study Summary

The BEET PAD Trial is a multi-centered double-blind randomized clinical trial designed to determine whether beetroot juice, compared to placebo, improves six-minute walk distance at four month follow-up in people with lower extremity peripheral artery disease (PAD). Investigators hypothesize that by simultaneously increasing lower extremity perfusion, gastrocnemius muscle mitochondrial activity, and myofiber health and regeneration, beetroot juice will significantly improve walking performance in people with PAD. The primary aim is to determine whether beetroot juice significantly improves six-minute walk distance at 4-month follow-up in people with PAD, compared to placebo. Preliminary evidence suggests that beetroot juice has both acute and chronic effects on walking performance in PAD. The primary outcome will measure the combined acute and chronic effect of beetroot juice (i.e. the maximal effect) on change in 6-minute walk at 4-month follow-up. In secondary aims, investigators will distinguish between acute and chronic effects of beetroot juice on six-minute walk and delineate biologic pathways by which beetroot juice improves walking performance in PAD, by measuring change in gastrocnemius muscle perfusion (MRI arterial spin labeling) and gastrocnemius muscle health. The trial will assess the durability of beetroot juice effects on six-minute walk. Nitrate in beetroot juice is metabolized to nitrite and subsequently to NO, attaining peak nitrite levels 2.5 hours after ingestion. The trial will determine whether a higher peak or a greater increase in plasma nitrite at 2.5 hours after beetroot juice consumption at baseline has a greater effect on six-minute walk at 4-month follow-up, compared to a lower peak or a smaller increase, respectively.

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Beetroot juice

Study Locations (4)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago
  • University of Chicago - Chicago

Minnesota

  • University of Minnesota - Minneapolis

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2023-01-25
Est. Completion 2028-10-01
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT05624125

The ClinicalTrials.gov registry entry for NCT05624125 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (71% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05624125 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Minnesota, Virginia.

Frequently Asked Questions

What is clinical trial NCT05624125 about?

NCT05624125 is a clinical study titled "BEETroot Juice to Reverse Functional Impairment in PAD". The BEET PAD Trial is a multi-centered double-blind randomized clinical trial designed to determine whether beetroot juice, compared to placebo, improves six-minute walk distance at four month follow-up in people with lower extremity peripheral artery disease (PAD). Investigators hypothesize that by...

What is the current status of trial NCT05624125?

This trial is currently recruiting. It is a NA study. The enrollment target is 210 participants. The study started on 2023-01-25. Estimated completion is 2028-10-01.

What conditions does trial NCT05624125 study?

This clinical trial studies the following conditions: Peripheral Artery Disease.

What interventions are being tested in trial NCT05624125?

The interventions under investigation include: Placebo (OTHER), Beetroot juice (OTHER).

Who is sponsoring clinical trial NCT05624125?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05624125 being conducted?

This trial has 4 study locations across Illinois, Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.